News

Medtronic said the E-Pooled analysis, which included five-year data from the Endeavor I (E-I), Endeavor II (E-II), E-II Continued Access (CA), and Endeavor III (E-III) clinical studies, and

As per the terms of the merger agreement, Manhattan, upon the closing, issued 7.06 million shares of its common stock to Ariston stockholders and debt holders (which represents

Bydureon is the proposed brand name for Exenatide once weekly. It is an investigational, extended-release medication for type 2 diabetes designed to deliver continuous therapeutic levels of Exenatide

An industry veteran with over 20 years of experience, Mr Kissam joined Albemarle as VP of General Counsel and Secretary in 2003. Since that time, he has held

Vermillion’s OVA1 is a protein-based in vitro diagnostic multi-variate index assay (IVDMIA), a new class of software-based diagnostics, cleared by the FDA. The test utilizes five well-established biomarkers

Alexandra Wyke, head of PatientView, said many patients’ groups, majority in the US, had expressed concerns about soaring drug prices and lack of patient assistance programmes to low

The acquisition also provides new channels for maximizing the potential of converting sanofi-aventis’ prescription medicines to over-the-counter (OTC) products, beginning with Allegra (fexofenadine hydrochloride), which is expected to

An independent Data Safety Monitoring Committee (DSMC) recommended A4021018 to be stopped after concluding that the addition of figitumumab to erlotinib is unlikely to demonstrate an improvement in

CALGB 90401 is a multicenter, randomized, double-blinded, placebo-controlled Phase III study designed to evaluate Avastin plus docetaxel chemotherapy and prednisone, compared to docetaxel chemotherapy and prednisone alone in